http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101959513-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 |
| filingDate | 2008-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb6e3acd93dfd02bbf0c34029b2fdcc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64b7c8ad1fb9912fdf8eebb5f3e5c73 |
| publicationDate | 2011-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101959513-A |
| titleOfInvention | Novel pharmaceutical compositions |
| abstract | The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R<1> and R<2> are independently hydrogen, C1-6alkyl or C3-6cycloalkyl1-6galkyl; or R<1> and R<2>, together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; q is 1 or 2; R<3> and R<4> are hydrogen; or when q is 1, R<3> and R<4>, together with the interconnecting atoms, may form a cyclopropane ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R<5> is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; and either R<6> or R<7> is -O-R<8> or -OCH2R<8>, wherein the other R<6> or R<7> is hydrogen or R<5>; and wherein R<8> is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; or a pharmaceutically acceptable salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102188424-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104865336-A |
| priorityDate | 2007-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.